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Abstract
Background—Type 2 myocardial infarction and myocardial injury are common in clinical 
practice, but long-term consequences are uncertain. We aimed to define long-term outcomes and 
explore risk stratification in patients with type 2 myocardial infarction and myocardial injury. 
Methods—We identified consecutive patients (n=2,122) with elevated cardiac troponin I 
concentrations (5 μg/L) at a tertiary cardiac center. All diagnoses were adjudicated as per the 
Universal Definition of Myocardial Infarction. The primary outcome was all-cause death. 
Secondary outcomes included major adverse cardiovascular events (MACE; non-fatal 
myocardial infarction or cardiovascular death) and non-cardiovascular death. To explore 
competing risks, cause-specific hazard ratios were obtained using Cox regression models. 
Results—The adjudicated index diagnosis was type 1 or type 2 myocardial infarction or 
myocardial injury in 1,171 (55.2%), 429 (20.2%) and 522 (24.6%) patients, respectively. At five 
years, all-cause death rates were higher in those with type 2 myocardial infarction (62.5%) or 
myocardial injury (72.4%) compared with type 1 myocardial infarction (36.7%). The majority of 
excess deaths in those with type 2 myocardial infarction or myocardial injury were due to non-
cardiovascular causes (HR 2.32, 95%CI 1.92-2.81, versus type 1 myocardial infarction). Despite 
this, the observed crude MACE rates were similar between groups (30.6% versus 32.6%), with 
differences apparent after adjustment for co-variates (HR 0.82, 95%CI 0.69-0.96). Coronary 
heart disease was an independent predictor of MACE in those with type 2 myocardial infarction 
or myocardial injury (HR 1.71, 95%CI 1.31-2.24).  
Conclusions—Despite an excess in non-cardiovascular death, patients with type 2 myocardial 
infarction or myocardial injury have a similar crude rate of major adverse cardiovascular events
to those with type 1 myocardial infarction. Identifying underlying coronary heart disease in this 
vulnerable population may help target therapies that could modify future risk.  
Key Words: acute coronary syndrome; myocardial infarction; survival; type 2 myocardial 
infarction
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Clinical Perspective
What is new? 
x We report long term outcomes at 5 years in consecutive patients with type 1 or type 2 
myocardial infarction, or myocardial injury. 
x Two-thirds of patients with type 2 myocardial infarction or myocardial injury are dead at 
5 years, with a similar rate of future non-fatal myocardial infarction or cardiovascular 
death as those with type 1 myocardial infarction.  
x The presence of coronary artery disease is an independent predictor of future 
cardiovascular risk in patients with type 2 myocardial infarction or myocardial injury.  
What are the clinical implications?
x Clinicians should consider risk stratification in patients with type 2 myocardial infarction 
or myocardial injury for the likelihood of coronary artery disease.
x Prospective clinical trials are needed to define the efficacy and safety of secondary 
prevention therapies in patients with type 2 myocardial infarction or myocardial injury, 
which have the potential to modify future outcomes.  by guest on N
ovem
ber 30, 2017
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The diagnostic criteria for acute myocardial infarction were updated to accommodate the 
introduction of more sensitive cardiac troponin assays, and in recognition of the wide range of
conditions that are associated with myocardial injury.1 The third universal definition of 
myocardial infarction recommends a classification based on etiology, where type 1 myocardial 
infarction is due to plaque rupture or erosion with atherothrombotic consequences, and type 2 
myocardial infarction due to myocardial oxygen supply-demand imbalance in the absence of 
atherothrombosis. Patients with elevated cardiac troponin concentrations who do not have overt 
myocardial ischemia are classified as having myocardial injury.2 Whilst these diagnostic 
categories are considered distinct in guidelines, implementation in clinical practice has been 
challenging due to similarities between patients with type 2 myocardial infarction and 
myocardial injury, with the implications of these diagnoses uncertain.
The Global Task Force is reviewing the classification of myocardial infarction, and 
recognizes the need to provide greater clarity for clinicians in practice.3 Whilst patients with type 
2 myocardial infarction and myocardial injury have higher crude rates of all-cause death
compared with those with type 1 myocardial infarction,4-9 differences do not always persist in 
adjusted analyses,10,11 and few studies report cause of death or risk of future cardiovascular 
events.12 If patients with type 2 myocardial infarction are at increased risk of cardiovascular 
events attributable to atherosclerotic disease, then targeted investigation and preventative 
therapies have the potential to modify outcomes.  
In consecutive patients with elevated cardiac troponin concentrations measured using a 
sensitive assay, we previously observed that the diagnosis of type 2 myocardial infarction or 
myocardial injury was as common as type 1 myocardial infarction.4 Here we report outcomes for 
these patients, and determine the clinical features associated with major adverse cardiovascular 
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events, with the aim of improving risk stratification in patients with type 2 myocardial infarction 
or myocardial injury. 
Methods
Transparency and openness promotion 
The analysis code for this study has been made available online (Supplemental Appendix 1).
The data will not be made available to other researchers for the purposes of reproducing the 
results due to lack of data sharing approval.  
Study population
Consecutive hospital inpatients with elevated cardiac troponin I concentrations J/) 
were identified at a tertiary cardiac center (Royal Infirmary of Edinburgh, Scotland, UK) during 
the validation (January 19th to July 31st 2008) and implementation (January 19th to July 31st 
2009) phases of a contemporary sensitive cardiac troponin I assay.4,13 We included all patients in 
whom cardiac troponin was requested by the attending clinician, regardless of suspected etiology 
or hospital department. All clinical details were obtained using an electronic patient record 
(TrakCare, InterSystems, Cambridge, MA). We excluded patients admitted for elective 
procedures, those with incomplete electronic hospital records, and patients who were not 
residents to ensure follow up was complete. 
Cardiac troponin assay 
Plasma cardiac troponin concentrations were measured using a contemporary sensitive cardiac 
troponin I assay (ARCHITECTSTAT, Abbott Laboratories, Abbott Park, IL). The study was 
divided into validation and implementation phases.4,13 Only cardiac troponin concentrations 
above the diagnostic threshold of the previous generation assay (J/) were reported to 
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clinicians during the validation phase, whereas concentrations above a revised diagnostic 
threshold J/) were reported during the implementation phase. The 99th centile of this 
assay is 0.028 μg/L; however, a diagnostic threshold of J/ was implemented as this was 
the minimum concentration where the coefficient of variation was <10% under local laboratory 
conditions. All troponin results were available to the research team irrespective of study phase.
Diagnostic classification
All diagnoses were classified as per the third universal definition of myocardial infarction.2,4
Patients were classified as having a type 1 myocardial infarction when myocardial necrosis 
occurred in the context of a presentation with suspected acute coronary syndrome with 
symptoms of myocardial ischemia, or evidence of myocardial ischemia on the 
electrocardiogram. Patients with symptoms or signs of myocardial ischemia that were thought to 
be due to increased oxygen demand (e.g. tachyarrhythmia or hypertrophy) or decreased supply 
(e.g. hypotension, hypoxia or anaemia) and myocardial necrosis in the context of an alternative 
clinical diagnosis were classified as having a type 2 myocardial infarction. Myocardial injury 
was defined as evidence of myocardial necrosis in the absence of any symptoms or signs of 
myocardial ischemia. For this analysis, we excluded patients classified as having type 3, type 4a
or 4b, or type 5 myocardial infarction. Each case was reviewed and classified independently by 
two cardiologists, and any discrepancies were resolved by consensus through in-depth review of 
source data. Further information on the adjudication process is provided in Supplemental 
Appendix 2.
Clinical outcomes
Clinical outcomes were identified using local and national population registries. We determined
death using TrakCare (InterSystems, Cambridge, MA) and the National Register of Scotland 
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(NRS), with future hospitalization for myocardial infarction or heart failure identified using an 
extract from the Scottish Morbidity Record (SMR01). We defined death from a cardiovascular 
cause where one of the following ICD10 codes were listed as primary cause of death: I20-25, 
I34-37, I42-43, I46, I48-51 and I60-69 (Supplemental Appendix 3). The primary outcome was 
all cause death. Secondary outcomes included major adverse cardiovascular events (MACE; 
defined as cardiovascular death or subsequent myocardial infarction), non-fatal myocardial 
infarction, fatal myocardial infarction, hospitalization with heart failure, and non-cardiovascular 
death. We obtained follow up for all patients until the primary outcome or date of censoring (16th
November 2015). 
Ethical considerations
The parent study protocol evaluated the implementation of a sensitive cardiac troponin assay,
and was deemed to fall under the remit of audit and service evaluation by the NHS Lothian 
Regional Ethics Committee, therefore formal ethical approval was not required. For this study, 
we received approval from the Caldicott guardian to obtain long term follow up through local 
and national registries. 
Statistical analysis 
Baseline characteristics were summarized as mean (SD) or median (IQR) as appropriate, with 
patients grouped based on the classification of myocardial infarction. Crude incidence rates for
primary and secondary outcomes were calculated, with risk ratios obtained using a generalized 
linear model with a log link, Poisson error distribution and robust variance estimates.14 We
adjusted for clinically relevant covariates including age, sex, renal function (estimated 
glomerular filtration rate, eGFR), hemoglobin (g/L), diabetes mellitus, hypertension, coronary 
heart disease (defined as previous myocardial infarction, coronary revascularization or known 
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angina pectoris), stroke, peripheral vascular disease or cigarette smoking. The study period 
included a lowering of the upper reference limit for cardiac troponin from 0.20 μg/L (validation 
phase) to 0.05 μg/L (implementation phase), and we therefore included study phase in all 
models. We repeated these analyses among only those patients who survived 30 days after 
presentation, defining the start of the follow-up period as 30 days post presentation. To explore 
competing risks, cause-specific hazard ratios were obtained using Cox regression models for 
type 1 myocardial infarction versus type 2 myocardial infarction or myocardial injury for MACE 
and non-cardiovascular death. Penalised splines were used to accommodate departures from 
linearity. We examined for non-proportional hazards graphically and via the method proposed by 
Grambsch and Therneau.15 In patients who survived to 30 days, we explored associations 
between covariates and future risk of MACE. Cumulative incidence plots were produced for 
secondary cardiovascular outcomes, which also illustrate the competing risk of non-
cardiovascular death. We report 95% confidence intervals for all estimates, with all analyses 
performed using R (Version 3.2.2) using the survival and cmprsk packages.16 
Results
We identified 2,929 consecutive patients with elevated cardiac troponin concentrations 
μg/L) of whom 807 met our exclusion criteria (Supplemental Figure 1). In the study population 
(n=2,122), the adjudicated diagnosis was type 1 myocardial infarction in 1,171 patients (55.2%), 
type 2 myocardial infarction in 429 patients (20.2%) and myocardial injury in 522 patients 
(24.6%; Table 1).  
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Clinical characteristics
Patients with type 2 myocardial infarction or myocardial injury were older, and there were a 
higher proportion of women than men compared to patients with type 1 myocardial infarction. 
Anaemia or renal impairment was more common in patients with type 2 myocardial infarction or 
myocardial injury. A history of previous coronary revascularization was more frequent in those 
with type 1 myocardial infarction. At presentation, the prescription of anti-platelet, anti-
hypertensive and lipid lowering therapies was similar across all patients (Table 1). The most 
common diagnoses in patients with type 2 myocardial infarction or myocardial injury were
cardiac arrhythmia, decompensated left ventricular failure, pneumonia or long bone fracture, 
with variation in prevalence by classification (Supplemental Table 1).
Clinical outcomes at five years in all patients
During 8,809 person years follow up (median 4.9 years), death from any cause occurred in 1,231 
patients (58%). In patients with type 2 myocardial infarction, at five years, the observed risk of 
death was higher compared to those with type 1 myocardial infarction (62.5% versus 36.7%, 
unadjusted relative risk (RR) 2.15, 95% confidence intervals (95%CI) 1.82-2.55 . After 
incorporating age, sex, renal function, hemoglobin and other clinically relevant co-variates, the 
adjusted RR fell to 1.51, (95%CI 1.21-1.87, Table 2, Figure 1).
 The five-year risk of non-fatal myocardial infarction or cardiovascular death (MACE) 
was similar in patients with type 2 compared to type 1 myocardial infarction (30.1% versus
32.6%, unadjusted RR 0.92, 95% CI 0.77-1.09, Figure 2), but lower after adjustment for age, sex 
and other co-variates (adjusted RR 0.74, 95%CI 0.62-0.88). Adjusting for the same co-variates, 
the cause-specific hazard ratio for MACE (with non-cardiovascular mortality as the competing 
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outcome) was similar to the relative risk (HR 0.82 95%CI 0.69-0.96, Table 3, Supplemental 
Table 2).  
 For the individual components of MACE, the risk of non-fatal myocardial infarction was 
lower in those with type 2 myocardial infarction compared to type 1 myocardial infarction 
(10.0% versus 17.8%, adjusted RR 0.58, 95%CI 0.44-0.77). Whilst the crude rates of 
cardiovascular death were higher for type 2 myocardial infarction compared to type 1 myocardial 
infarction (24.2% versus 21.6%) the adjusted relative risk was lower at 0.85 (95%CI 0.70-1.03).
Risks of fatal-myocardial infarction and hospitalization with heart failure were comparable 
across groups (Table 2). Non-cardiovascular death was higher in patients with type 2 myocardial 
infarction compared to type 1 myocardial infarction (35.7% versus 13.2%, adjusted RR 1.66, 
95%CI 1.40-1.98, Figure 2).  
We found similar relative risks for patients with myocardial injury compared to type 1 
myocardial infarction for most primary and secondary outcomes, but a lower risk of non-fatal 
myocardial infarction and higher risk of non-cardiovascular death were observed. Patients with
myocardial injury had a higher risk of all-cause death and heart failure hospitalization than 
patients with type 2 myocardial infarction (Supplemental Table 3). 
Clinical outcomes at five years in those who survive to 30 days 
In patients who survived from their initial presentation to 30 days, death from any cause occurred 
in 31% (333/1,074) of patients with type 1 myocardial infarction, 56.1% (207/368) of patients 
with type 2 myocardial infarction and 67% (293/437) of patients with myocardial injury
(Supplemental Table 4). The adjusted relative risk of death for patients with type 2 myocardial 
infarction versus type 1 myocardial infarction was similar to that observed in the total population 
(adjusted RR 1.52, 95%CI 1.21-1.92). For all but one of the secondary outcomes, the relative 
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risks were similar to those obtained in the main analysis.  However, the association between type 
of myocardial infarction and risk of MACE was weaker than was observed in the whole 
population, occurring in 27.4% (101/368) of patients with type 2 myocardial infarction and 
27.7% (298/1,074) of patients with type 1 myocardial infarction, with an adjusted RR of 0.80 
(95%CI 0.65-0.98). 
In patients with type 2 myocardial infarction or myocardial injury, age, declining renal 
function, a history of diabetes mellitus, peripheral vascular disease and coronary artery disease 
were independent predictors of MACE at five years (Supplemental Table 5). The presence of 
coronary artery disease was associated with an increase in the cause-specific hazard ratio for
MACE at five years (HR 1.71, 95%CI 1.31-2.24), compared to those without coronary artery 
disease. When compared to patients with type 1 myocardial infarction, patients with type 2 
myocardial infarction or myocardial injury with coronary artery disease had a higher risk of 
MACE (RR 1.56, 95%CI 1.29-1.88). The adjusted cause-specific hazard ratio for MACE, which 
accounts for competing risk from non-cardiovascular death, was 1.05 (95%CI 0.85-1.30, Figure 
3). On discharge from hospital, patients with type 2 myocardial infarction or myocardial injury 
and a history of coronary artery disease were less likely than those with type 1 myocardial 
infarction to be prescribed aspirin (66.2% versus 90.7%), a statin (69.2% versus 86.0%) or an
ACE inhibitor (52.9% versus 71.3%, P<0.001 for all, Table 4).
Discussion
In a cohort of consecutive hospitalized patients with elevated cardiac troponin concentrations, we 
classified the diagnosis of myocardial infarction according to the universal definition and report 
outcomes after five years follow up. We make several observations that have implications for 
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clinical practice. First, over two-thirds of patients with type 2 myocardial infarction or 
myocardial injury are dead at five years. This mortality rate was twice that of patients with type 1 
myocardial infarction, with differences primarily due to an excess in non-cardiovascular deaths. 
Second, major adverse cardiovascular events occurred in one-third of patients, and rates were 
similar irrespective of diagnostic classification. In those patients with type 2 myocardial 
infarction or myocardial injury, the presence of coronary heart disease was one of the strongest 
predictors of MACE. Those patients with type 2 myocardial infarction or myocardial injury with 
known coronary artery disease were less likely to receive secondary prevention therapies 
compared to those with type 1 myocardial infarction. Identifying patients with elevated cardiac 
troponin concentrations in the context of an acute illness who have underlying coronary heart 
disease may provide an opportunity for clinicians to improve the targeting of preventative 
therapies and reduce the risk of cardiovascular events. 
Several studies demonstrate that the diagnosis of type 2 myocardial infarction is common 
in clinical practice, responsible for between 2% and 37% of all elevations in cardiac troponin in 
unselected hospitalized patients and between 5% to 71% in unselected patients attending the 
Emergency Department.17-21 Myocardial injury has been reported in up to 70% of unselected 
patients,5,22 but as the frequency of diagnosis is not reported by the majority of studies, failure to 
classify patients according to the criteria set out in the universal definition may inflate the 
incidence of type 2 myocardial infarction.23 Both type 2 myocardial infarction and myocardial 
injury increase the risk of all-cause death at up to three years.5-9,21,23-25 We now provide outcome 
data at five years demonstrating that two-thirds of patients with type 2 myocardial infarction or 
myocardial injury are dead with twice the event rate of patients with type 1 myocardial 
infarction. 
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 One of the key limitations of prior analyses is the majority have not reported the specific 
cause of death, and therefore estimates of the proportion of events which may be attributable to 
cardiovascular disease, are lacking.26,27 We found the excess in all-cause death in patients with 
type 2 myocardial infarction or myocardial injury was largely attributable to a three-fold increase 
in non-cardiovascular death. As patients with type 2 myocardial infarction or myocardial injury 
are older, and have a higher prevalence of anaemia, renal impairment, and other co-morbidities, 
this is perhaps unsurprising. Nonetheless, it is notable that the crude risk of MACE in patients 
with type 2 myocardial infarction or myocardial injury was similar to that in patients with type 1 
myocardial infarction. In models taking into account the differences in age, sex and other 
characteristics between patients with different index diagnoses, the risk of subsequent 
cardiovascular events was around 25% lower in patients with type 2 myocardial infarction or 
myocardial injury than in patients with type 1 myocardial infarction. This may in part be 
attributable to competing risks, with the much higher rates of non-cardiovascular death reducing
the pool of patients at risk of having a cardiovascular event. However, competing risks are not 
the only explanation for the lower rates of MACE in patients with type 2 myocardial infarction 
or myocardial injury, as in an adjusted analysis taking into account competing risks and other 
clinical variables, a difference in the cause-specific hazard ratio was still apparent between the 
groups.  
The diagnostic distinction between patients with type 2 myocardial infarction and 
myocardial injury is challenging, but worthwhile if the diagnosis conveys important prognostic 
information, or influences treatment decisions.7,28-30 In our analysis, the recommended 
classification of type 2 myocardial infarction or myocardial injury did not differentially identify 
those patients at risk of MACE. This observation is consistent with previous studies and suggests 
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alternate strategies for risk stratification may be required. In patients with type 2 myocardial 
infarction, the presence of obstructive coronary artery disease may influence prognosis. 
Outcomes from the SWEDEHEART registry of 41,817 patients with type 1 or 2 myocardial 
infarction demonstrated an increased risk of all-cause death in patients with type 2 myocardial 
infarction with obstructive coronary artery disease compared to those without.21 Similarly, in a 
recent analysis of the APACE cohort, Nestelberger et al found patients with type 2 myocardial 
infarction and coronary artery disease had a 90 day cardiovascular mortality of 3.6%, with no 
deaths observed in those without coronary artery disease.31 Our analysis supports these findings, 
with coronary artery disease one of the strongest predictors of MACE in patients with type 2 
myocardial infarction or myocardial injury. The prevalence of coronary artery disease in patients
with type 2 myocardial infarction or myocardial injury was 42% in our cohort, and varies 
between 36% to 78% in previous reports.7,11,21,22,32 However, estimates obtained from registry 
studies are hindered by selection bias as those who undergo angiography will have a higher pre-
test probability of coronary artery disease, and the true prevalence of coronary artery disease in 
this group of patients remains uncertain. 33  
 Importantly, patients with type 2 myocardial infarction or myocardial injury receive 
fewer prescriptions for preventative therapies compared to those with type 1 myocardial 
infarction.9,10,20-23 To date, there have been no randomized controlled trials evaluating secondary 
prevention in this population, and there are no formal recommendations for risk assessment or 
treatment.30 Given the current heterogeneity in application of the Universal Definition of 
Myocardial Infarction, the feasibility of delivering such a study with comparable observations 
across multiple healthcare settings is uncertain. Primary prevention guidelines recommend statin 
therapy where the predicted ten year risk of adverse cardiovascular events exceeds 10%.34 In our 
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study, patients who survive their initial presentation with type 2 myocardial infarction and are 
not already known to have coronary artery disease, the rate of MACE exceeds 10% at one year. 
Whilst this may be partially attributable to age and the presence of co-morbidities, a significant 
proportion may have unrecognized coronary artery disease and may benefit from further 
investigation or preventative therapies. 
 We believe clinicians should adopt a pragmatic approach, and risk stratify individual 
patients based on their likelihood of coronary artery disease.29,30 There are no risk assessment 
tools validated for use in this setting, therefore clinicians must review the presenting symptoms, 
medical history, cardiovascular risk factors, serial 12-lead electrocardiograms and any available 
imaging findings and apply clinical judgement. Where the probability of coronary disease is 
high, it may be reasonable to commence secondary prevention with aspirin and a statin in the 
absence of contraindications. If patients with type 2 myocardial infarction are found to have 
obstructive coronary artery disease, revascularization could plausibly reduce the risk of future 
cardiac events, but this strategy has not been evaluated. Where the probability of coronary 
disease is intermediate or low, further investigation (invasive or CT coronary angiography) 
should be considered to identify patients with underlying coronary artery disease, where the 
benefits of secondary prevention are well recognized. The optimal timing for investigation in this 
group of patients is also uncertain. Where the probability of type 1 myocardial infarction is high, 
invasive assessment should be considered on an urgent basis in line with standard practice. In 
those patients where myocardial injury or infarction is secondary to oxygen supply-demand 
imbalance, further assessment may need to be deferred until the patient has recovered from their 
primary illness. Furthermore, a recognition that these patients are at increased risk of non-
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cardiovascular events may lead to an improvement in outcomes, through better monitoring or 
intensification of treatment of the primary presenting condition.  
There are important limitations to the data presented. The study population was identified 
on the basis of an elevated troponin I concentration measured using a contemporary sensitive 
assay with a diagnostic threshold of 0.05 μg/L, and the true prevalence of myocardial injury and 
infarction could be higher using a lower threshold or a high-sensitivity cardiac troponin assay. 
Whilst two cardiologists adjudicated all index diagnoses using all available clinical information,
with excellent intra-observer agreement, there remains potential for misclassification, 
particularly for type 2 myocardial infarction and myocardial injury. There is likely to be 
variation in the in-hospital treatments received which we could not adjust for, nor could we 
adjust for illness severity. As previously reported, a low proportion of patients with type 2 
myocardial infarction or myocardial injury underwent inpatient coronary angiography.4 We
therefore defined coronary artery disease based on a diagnosis of angina, previous myocardial 
infarction or previous coronary revascularization, which is likely to significantly underestimate 
the prevalence of coronary artery disease. Finally, subsequent hospitalizations and cardiovascular 
or non-cardiovascular death were determined using ICD-10 coding obtained from regional and 
national registry data, where there is the potential for both diagnostic and coding error. We were 
therefore not able to determine the incidence of subsequent type 1 or type 2 myocardial 
infarction.  
Conclusions  
Over two-thirds of patients admitted to hospital with type 2 myocardial infarction or myocardial 
injury die within five years, with the majority of deaths due to non-cardiovascular causes. 
Nonetheless, major adverse cardiovascular events occur in one-third of patients with elevated 
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cardiac troponin concentrations, irrespective of whether myocardial necrosis was spontaneous or 
secondary to another acute illness. Whilst patients with type 1 myocardial infarction were at 
highest risk, there was no separation of risk between those with a diagnosis of type 2 myocardial 
infarction or myocardial injury. In contrast, those patients with type 2 myocardial infarction or 
myocardial injury known to have coronary artery disease are at highest risk of cardiovascular 
events, and efforts to diagnose coronary artery disease may provide opportunities to target 
preventative therapies and improve patient outcomes.
Sources of Funding  
This work was supported by the British Heart Foundation (SP/12/10/29922 and 
PG/15/51/31596). ARC, NLM and DEN are supported by Clinical Research Training Fellowship 
(FS/16/75/32533), Butler Senior Clinical Research Fellowship (FS/16/14/32023) and Chair 
(CH/09/002) awards from the British Heart Foundation. DM is supported via an intermediate 
clinical fellowship from the Wellcome Trust (201492-Z-16-Z). AA is supported by a research 
fellowship from Chest Heart and Stroke Scotland (15/A163). DEN is the recipient of a Wellcome 
Trust Senior Investigator Award (WT103782AIA).
Disclosures 
AA and ASVS have received honoraria from Abbott Diagnostics. ARC has received honoraria 
from Abbott Diagnostics and Astra-Zeneca. NLM has acted as a consultant for Abbott 
Diagnostics, Beckman-Coulter, Roche and Singulex. All other authors have nothing to declare. 
The funders had no role in the design or conduct of the study, or in the collection, analysis and 
interpretation of data, or preparation, review or approval of the manuscript.
 by guest on N
ovem
ber 30, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
10.1161/CIRCULATIONAHA.117.031806
18
References
1. White HD, Thygesen K, Alpert JS, Jaffe AS. Clinical implications of the Third Universal 
Definition of Myocardial Infarction. Heart. 2014;100:424-434.  
2. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD. Third universal 
definition of myocardial infarction. Eur Heart J. 2012;33:2551-2567. 
3. Alpert JS, Thygesen KA. The Case for a Revised Definition of Myocardial Infarction – The 
Ongoing Conundrum of Type 2 Myocardial Infarction vs Myocardial Injury. JAMA Cardiol.
2016;1:249-250. 
4. Shah AS, McAllister DA, Mills R, Lee KK, Churchhouse AM, Fleming KM, Layden E, 
Anand A, Fersia O, Joshi NV, Walker S, Jaffe AS, Fox KA, Newby DE, Mills NL. Sensitive 
troponin assay and the classification of myocardial infarction. Am J Med. 2015;128:493-
501.e3.  
5. Javed U, Aftab W, Ambrose JA, Wessel RJ, Mouanoutoua M, Huang G, Barua RS, Weilert 
M, Sy F, Thatai D. Frequency of elevated troponin I and diagnosis of acute myocardial 
infarction. Am J Cardiol. 2009;104:9-13. 
6. El-Haddad H, Robinson E, Swett K, Wells GL. Prognostic implications of type 2 myocardial 
infarctions. World J Cardiovasc Dis. 2012;2:237–241. 
7. Sarkisian L, Saaby L, Poulsen TS, Gerke O, Jangaard N. Clinical Characteristics and 
Outcomes of Patients with Myocardial Infarction, Myocardial Injury, and Nonelevated 
Troponins. Am J Med. 2016;129:446.e5-446.e21. 
8. Saaby L, Poulsen TS, Diederichsen AC, Hosbond S, Larsen TB, Schmidt H, Gerke O, Hallas 
J, Thygesen K, Mickley H. Mortality rate in type 2 myocardial infarction: observations from 
an unselected hospital cohort. Am J Med. 2014;127:295–302. 
9. Stein, GY, Herscovic G, Korenfeld R, Matetzky S, Gottlieb S, Alon D, Gevrielov-Yusim N, 
Iakobishvili Z, Fuchs S. Type-II myocardial infarction–patient characteristics, management 
and outcomes. PLoS One. 2014;9:e84285. 
10. Sandoval Y, Smith SW, Sexter A, Thordsen SE, Bruen CA, Carlson MD, Dodd KW, Driver 
BE, Hu Y, Jacoby K, Johnson BK, Love SA, Moore JC, Schulz K, Scott NL, Apple FS. Type 
1 and 2 Myocardial Infarction and Myocardial Injury: Clinical Transition to High-Sensitivity 
Cardiac Troponin I. Am J Med. 2017. doi: 10.1016/j.amjmed.2017.05.049. [Epub ahead of 
print] 
11. Neumann JT, Sörensen NA, Rübsamen N, Ojeda F, Renné T, Qaderi V, Teltrop E, Kramer S, 
Quantius L, Zeller T, Karakas M, Blankenberg S, Westermann D. Discrimination of patients 
with type 2 myocardial infarction. Eur Heart J. 2017. doi : 10.1093/eurheartj/ehx457. [Epub 
ahead of print] 
12. Gaggin HK, Liu Y, Lyass A, van Kimmenade RRJ, Motiwala SR, Kelly NP, Mallick A, 
Gandhi PU, Ibrahim NE, Simon ML, Bhardwaj A, Belcher AM, Harisiades JE, Massaro JM, 
D’Agostino RB Sr, Januzzi JL Jr. Incident Type 2 Myocardial Infarction in a Cohort of 
Patients Undergoing Coronary or Peripheral Arterial Angiography. Circulation.
2017;135:116-127. 
13. Mills NL, Churchhouse AMD, Lee KK, Anand A, Gamble D, Shah AS, Paterson E, 
MacLeod M, Graham C, Walker S, Denvir MA, Fox KA, Newby DE. Implementation of a 
sensitive troponin I assay and risk of recurrent myocardial infarction and death in patients 
with suspected acute coronary syndrome. JAMA. 2011;305:1210–1216. 
 by guest on N
ovem
ber 30, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
10.1161/CIRCULATIONAHA.117.031806
19
14. Yelland LN, Salter AB, Ryan P. Relative Risk Estimation in Randomized Controlled Trials: 
A Comparison of Methods for Independent Observations. International Journal of 
Biostatistics. 2011;7:1-31.
15. Grambsch PM, Therneau TM. Proportional Hazards Tests and Diagnostics Based on 
Weighted Residuals. Biometrika. 1994;81:515-526. 
16. R Core Team. R: A Language and Environment for Statistical Computing. 2015. R
Foundation for Statistical Computing, Vienna, Austria. https://www.R-project.org/. 
17. Melberg T, Burman R, Dickstein K. The impact of the 2007 ESCACC-AHA-WHF Universal 
definition on the incidence and classification of acute myocardial infarction: a retrospective 
cohort study. Int J Cardiol. 2010;139:228–233. 
18. Shah ASV, Griffiths M, Lee KK, McAllister DA, Hunter AL, Ferry AV, Cruikshank A, Reid 
A, Stoddart M, Strachan F, Walker S, Collinson PO, Apple FS, Gray AJ, Fox KA, Newby 
DE, Mills NL. High sensitivity cardiac troponin and the under-diagnosis of myocardial 
infarction in women: prospective cohort study. BMJ. 2015;350:g7873–3. 
19. Smith SW, Diercks DB, Nagurney JT, Hollander JE, Miller CD, Schrock JW, Singer AJ, 
Apple FS, McCullough PA, Ruff CT, Sesma A Jr, Peacock WF. Central versus local 
adjudication of myocardial infarction in a cardiac biomarker trial. Am Heart J. 2013;165:273-
279.
20. Sandoval Y, Thordsen SE, Smith SW, Schulz KM, Murakami MM, Pearce LA, Apple FS. 
Cardiac troponin changes to distinguish type 1 and type 2 myocardial infarction and 180-day 
mortality risk. Eur Heart J Acute Cardiovasc Care. 2014;3:317-325. 
21. Baron T, Hambraeus K, Sundström J, Erlinge D, Jernberg T, Lindahl B; on behalf of the 
TOTAL-AMI study group. Impact on Long-Term Mortality of Presence of Obstructive 
Coronary Artery Disease and Classification of Myocardial Infarction. Am J Med.
2016:129;398-406.  
22. Saaby L, Poulsen TS, Hosbond S, Larsen TB, Pyndt Diederichsen AC, Hallas J, Thygesen K, 
Mickley H. Classification of myocardial infarction: frequency and features of type 2 
myocardial infarction. Am J Med. 2013;126:789-797. 
23. Baron T, Hambraeus K, Sundstrom J, Erlinge D, Jernberg T, Lindahl B; TOTAL-AMI study 
group. Type 2 myocardial infarction in clinical practice. Heart. 2015;101:101-106.  
24. Morrow DA, Wiviott SD, White HD, Nicolau JC, Bramucci E, Murphy SA, Bonaca MP, 
Ruff CT, Scirica BM, McCabe CH, Antman EM, Braunwald E. Effect of the novel 
thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural 
myocardial infarction in the trial to assess improvement in therapeutic outcomes by 
optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38: an 
application of the classification system from the universal definition of myocardial infarction. 
Circulation. 2009;119:2758-2764.  
25. Bonaca MP, Wiviott SD, Braunwald E, Murphy SA, Ruff CT, Antman EM, Morrow DA. 
American College of Cardiology/American Heart Association/European Society of 
Cardiology/World Heart Federation universal definition of myocardial infarction 
classification system and the risk of cardiovascular death: observations from the TRITON-
TIMI 38 trial. Circulation. 2012;125:577-583.  
26. Sandoval Y, Thygesen K. Myocardial Infarction Type 2 and Myocardial Injury. Clin Chem.
2017;63:101-107. 
27. Sandoval Y. Improving our understanding of type 2 myocardial infarction and myocardial 
injury. Trends Cardiovasc Med. 2017;27:418-419.
 by guest on N
ovem
ber 30, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
10.1161/CIRCULATIONAHA.117.031806
20
28. Collinson P, Lindahl B. Type 2 myocardial infarction: the chimera of cardiology? Heart.
2015;101:1697-1703.
29. Chapman AR, Mills NL. Refining the diagnosis of type 2 myocardial infarction. JAMA
Cardiol. 2017;2:106.
30. Chapman AR, Adamson PA, Mills NL. Assessment and classification of myocardial injury 
and infarction. Heart. 2017;103:10-18.  
31. Nestelberger T, Boeddinghaus J, Badertscher P, Twerenbold R, Wildi K, Breitenbücher D, 
Sabti Z, Puelacher C, Rubini Gimenez M, Kozhuharov N, Strebel I, Sazgary L, Schneider D, 
Jann J, du Fay de Lavallaz J, Miro O, Martin-Sanchez FJ, Morawiec B, Kawecki D, Muzyk 
P, Keller DI, Geigy N, Osswald S, Reichlin T, Mueller C on behalf of the APACE 
investigators. Effect of Definition on Incidence and Prognosis of Type 2 Myocardial 
Infarction. J Am Coll Cardiol. 2017;70:1558-1568.  
32. Ambrose JA, Loures-Vale A, Javed U, Buhari CF, Aftab W. Angiographic correlates in type 
1 and 2 MI by the universal definition. JACC Cardiovasc Imaging. 2012;5:463-464 
33. Januzzi JL, Sandoval Y. The Many Faces of Type 2 Myocardial Infarction. J Am Coll 
Cardiol. 2017;70:1569-1572.
34. National Institute for Health and Care Excellence (NICE). Cardiovascular disease: risk 
assessment and reduction, including lipid modification: Clinical Guideline [CG181]. Date 
published July 2014. Date accessed July 2017. Available online at 
https://www.nice.org.uk/guidance/cg181/.
 by guest on N
ovem
ber 30, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
10.1161/CIRCULATIONAHA.117.031806
21
Table 1. Baseline characteristics of the study population 
Type 1 Myocardial 
Infarction (n=1,171)
Type 2 Myocardial 
Infarction (n=429)
Myocardial Injury 
(n=522)
P value
Baseline Characteristics
Age 68 (14) 75 (14) 76 (13) <0.001
Male (%) 709 (60.5) 222 (51.7) 260 (49.8) <0.001
Past Medical History
Diabetes Mellitus (%) 185 (16.7) 93 (21.7) 96 (18.7) 0.072
Hypertension (%) 533 (48.2) 254 (59.3) 303 (58.9) <0.001
Hyperlipidaemia (%) 539 (48.6) 177 (41.5) 202 (39.5) 0.001
Family History (%) 193 (18.1) 14 (3.3) 10 (2.0) <0.001
Ischaemic Heart Disease (%) 497 (44.7) 191 (44.6) 186 (36.3) 0.004
Previous MI (%) 231 (23.9) 109 (26.0) 107 (20.9) 0.183
Previous Stroke (%) 92 (8.3) 48 (11.2) 86 (16.8) <0.001
Peripheral Vascular Disease (%) 85 (7.7) 29 (6.8) 39 (7.6) 0.831
Previous PCI (%) 153 (14.7) 17 (4.0) 23 (4.5) <0.001
Previous CABG (%) 62 (6.3) 30 (7.1) 32 (6.2) 0.849
Smoker (%) 380 (34.0) 62 (14.5) 73 (14.0) <0.001
Admission Medication
Aspirin (%) 413 (49.7) 175 (44.1) 207 (45.9) 0.141
Clopidogrel (%) 100 (12.2) 25 (6.3) 26 (5.8) <0.001
Beta-blocker (%) 257 (31.2) 101 (25.7) 111 (24.6) 0.022
ACE Inhibitor (%) 300 (36.4) 136 (34.4) 158 (35.1) 0.782
Statin (%) 384 (46.5) 156 (39.5) 191 (42.4) 0.054
Long Acting Nitrate (%) 124 (15.1) 48 (12.2) 43 (9.6) 0.017
Calcium Channel Blocker (%) 165 (20.1) 65 (16.5) 67 (14.9) 0.050
GTN Spray (%) 250 (30.3) 76 (19.3) 63 (14.0) <0.001
Diuretic (%) 230 (27.9) 170 (43.0) 196 (43.6) <0.001
Warfarin (%) 35 (4.5) 38 (9.7) 52 (11.6) <0.001
Baseline Investigations
Haemoglobin (g/L) 133.9 (20.4) 121.4 (25) 120.2 (22.1) <0.001
Urea (mmol/L) 8.2 (9.4) 10 (7.1) 12.02 (11.5) <0.001
Creatinine (mmol/L) 106.8 (59.8) 132.5 (108.9) 155 (172.2) <0.001
Corrected eGFR (ml/min) 69 (26) 58 (28) 54 (32) <0.001
Cholesterol (mmol/L) 4.8 (1.3) 4.3 (1.2) 4.3 (1.4) <0.001
Troponin I (μg/L) 2.42 (0.27-15.23) 0.14 (0.07-0.66) 0.13 (0.06-0.39) <0.001
Values are mean (SD),median (IQR) or n(%). MI – myocardial infarction. PCI – percutaneous coronary intervention. 
CABG – coronary artery bypass grafting. ACE – angiotensin converting enzyme. GTN – glyceryl trinitrate, eGFR –
estimated glomerular filtration rate, Ischaemic Heart Disease – previous myocardial infarction or angina pectoris. P
values obtained from group-wise comparisons using Chi-square, Kruskal Wallis or one way analysis of variance tests as 
appropriate. 
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Table 2. Death and major cardiovascular events at 5 years stratified by diagnosis 
Type 1 MI 
(n=1,171)
Type 2 MI
(n=429)
Myocardial 
injury
(n=522)
Type 2 MI versus 
Type 1 MI
Myocardial Injury
versus Type 1 MI
Unadjusted 
RR (95% CI)
Adjusted RR 
(95% CI)
Unadjusted 
RR (95% CI)
Adjusted RR 
(95% CI)
Death from any cause 430 (36.7%) 268 (62.5%) 378 (72.4%) 2.15 (1.82-2.55) 1.51 (1.21-1.87) 2.88 (2.43-3.40) 2.09 (1.72-2.55)
MACE 382 (32.6%) 129 (30.1%) 162 (31.0%) 0.92 (0.77-1.09) 0.74 (0.62-0.88) 0.95 (0.81-1.11) 0.77 (0.66-0.89)
Non-fatal MI 209 (17.8%) 43 (10.0%) 35 (6.7%) 0.60 (0.45-0.79) 0.58 (0.44-0.77) 0.43 (0.31-0.58) 0.44 (0.32-0.60)
Cardiovascular death 253 (21.6%) 104 (24.2%) 145 (27.8%) 1.11 (0.92-1.34) 0.85 (0.70-1.03) 1.25 (1.07-1.46) 0.92 (0.79-1.07)
Fatal MI 32 (2.7%) 9 (2.1%) 18 (3.4%) 0.81 (0.45-1.46) 0.64 (0.37-1.11) 1.17 (0.81-1.71) 0.93 (0.64-1.34)
Heart failure hospitalization 103 (8.8%) 25 (5.8%) 48 (9.2%) 0.71 (0.50-1.02) 0.77 (0.54-1.12) 1.03 (0.81-1.32) 1.08 (0.86-1.35)
Non-cardiovascular death 155 (13.2%) 153 (35.7%) 218 (41.8%) 2.33 (1.99-2.71) 1.66 (1.40-1.98) 2.54 (2.33-2.89) 1.84 (1.61-2.11)
Event rates (number, %) for primary and secondary outcomes with adjusted relative risk (RR) and 95% confidence intervals (95% CI) at five 
years. MACE = major adverse cardiovascular events (non-fatal type 1 myocardial infarction or cardiovascular death), MI = myocardial 
infarction. For the composite of MACE, patients who experienced non-fatal myocardial infarction and subsequent cardiovascular death are 
counted once. Cause of death was not determined in 48 patients due to missing data. 
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Table 3. Cause-specific hazard ratio for MACE and non-cardiovascular death in patients with 
type 2 myocardial infarction or myocardial injury versus type 1 myocardial infarction in 
unadjusted and fully adjusted Cox-regression models.    
Major Adverse Cardiovascular Events
csHR (95% CI) P value
Model 1 1.16 (1.00-1.34) 0.052
Model 2 0.84 (0.72-0.98) 0.024
Model 3 0.74 (0.63-0.87) <0.001
Model 4 0.82 (0.69-0.96) 0.016
Non-Cardiovascular Death 
csHR (95% CI) P value
Model 1 3.73 (3.15-4.41) <0.001
Model 2 2.63 (2.21-3.12) <0.001
Model 3 2.27 (1.90-2.72) <0.001
Model 4 2.32 (1.92-2.81) <0.001
Model 1 – Unadjusted. Model 2 – Adjusted for Age and Sex. Model 3 – As per Model 2 with adjustment 
for estimated glomerular filtration rate.  Model 4: As per Model 3 with adjustment for haemoglobin, 
smoking, diabetes, hypertension, coronary artery disease, stroke, peripheral vascular disease and study 
phase. csHR- cause specific hazard ratio. Type 1 myocardial infarction as the referent group. P-value for 
inclusion of index diagnosis term. 
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Table 4. Recommended therapies at discharge in patients with type 1 myocardial infarction, type 2 myocardial 
infarction and myocardial injury who survive to 30 days, stratified by the presence of coronary artery disease.  
Type 1 Myocardial 
Infarction 
(n=1,074)
Type 2 Myocardial Infarction
or Myocardial Injury 
Known coronary artery 
disease 
(n=325)
Type 2 Myocardial 
Infarction or 
Myocardial injury
No known coronary 
artery disease
(n=467)
P value
Aspirin 896 (90.7%) 190 (66.2%) * 148 (37.7%) <0.001
Clopidogrel 823 (80.7%) 52 (17.6%) * 31 (7.6%) <0.001
Beta-blocker 651 (64.2%) 126 (42.6%) * 97 (23.7%) <0.001
ACE Inhibitor 724 (71.3%) 156 (52.9%) * 124 (30.2%) <0.001
Statin 872 (86.0%) 204 (69.2%) * 120 (29.3%) <0.001
Long acting nitrates 143 (14.1%) 77 (26.1%) * 12 (2.9%) <0.001
GTN Spray 671 (66.0%) 121 (41.0%) * 23 (5.6%) <0.001
Calcium Channel Blockers 165 (16.3%) 67 (22.7%) 43 (10.5%) <0.001
Warfarin 33 (3.4%) 44 (15.0%) * 64 (15.6%) <0.001
P values obtained from group-wise comparison using Chi-square test. *P<0.001 in post hoc analysis comparing patients 
with type 2 myocardial infarction or myocardial injury with coronary artery disease versus patients with type 1 myocardial 
infarction. 
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Figure Legends
Figure 1. Kaplan-Meier curves illustrating risk of death from any cause at five years stratified by 
index diagnosis, with table of number at risk. Pair-wise comparison of groups obtained using the 
log-rank test.  
Figure 2. Cumulative incidence curves illustrating risk of major adverse cardiovascular events 
(MACE; type 1 myocardial infarction or cardiovascular death) and competing risk of non-
cardiovascular death at five years stratified by index diagnosis. 
Figure 3. Cumulative incidence curves illustrating risk of major adverse cardiovascular events 
(MACE; type 1 myocardial infarction or cardiovascular death) and competing risk of non-
cardiovascular death in those who survive to 30 days in patients with type 1 myocardial 
infarction, and in those with type 2 myocardial infarction or myocardial injury stratified by 
known coronary artery disease (CAD). 
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Supplemental Table 1. Most common primary discharge diagnoses in patients with an 
adjudicated diagnosis of type 2 myocardial infarction or myocardial injury.  
 
 
  
Type 2 Myocardial Infarction Myocardial Injury 
Arrhythmia (19.1%, 82/429) Heart Failure (12.8%, 67/522) 
Pneumonia (13.5%, 58/429) Arrhythmia (10.9%, 57/522) 
Heart Failure (12.4%, 53/429) Pneumonia (9.6%, 50/522) 
Fracture (4.2%, 18/429) Fracture (8.0%, 42/522) 
	 3 
Supplemental Table 2 – Cause-specific hazard ratios for major adverse cardiovascular 
events in all patients.  
 
 
Penalised smoothing splines used for age and eGFR (estimated glomerular filtration rate) in multivariate model. Type 1 Myocardial Infarction as 
referent group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Major Adverse Cardiovascular Events (MACE)  
 Unadjusted HR (95% CI) 
Adjusted HR 
(95% CI) 
Age (per 10-year increase) 1.60 (1.50-1.70) - 
Sex (male) 0.85 (0.73-0.98) 1.09 (0.93-1.28) 
Haemoglobin (per 10 g/L reduction) 1.18 (1.14-1.21) 1.07 (1.03-1.11) 
eGFR (per 10 ml/min reduction) 1.20 (1.17-1.24) - 
Smoking 0.66 (0.55-0.79) 1.26 (1.02-1.56) 
Diabetes Mellitus 1.77 (1.49-2.10) 1.36 (1.14-1.64) 
Hypertension 1.66 (1.42-1.93) 1.05 (0.89-1.24) 
Coronary Artery Disease 2.52 (2.16-2.94) 1.80 (1.52-2.14) 
Stroke 1.88 (1.53-2.31) 1.10 (0.89-1.38) 
Peripheral Vascular Disease 2.07 (1.65-2.59) 1.45 (1.14-1.86) 
Validation phase 1.21 (1.04-1.40) 1.16 (0.99-1.35) 
Type 1 Myocardial Infarction 1.00 1.00 
Type 2 Myocardial Infarction / 
Myocardial Injury 1.16 (1.00-1.34) 0.82 (0.69-0.96) 
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Supplemental Table 3 – Adjusted relative risks of primary and secondary outcomes for 
patients with myocardial injury versus type 2 myocardial infarction  
 
 
 Myocardial Injury versus  
Type 2 MI 
 
Adjusted RR  
(95% CI) 
Death from any cause 1.27 (1.08-1.48) 
MACE  0.99 (0.87-1.13) 
   Non-fatal MI  0.80 (0.61-1.03) 
   Cardiovascular death 1.07 (0.94-1.22) 
Fatal MI 1.18 (0.87-1.58) 
Heart failure hospitalization 1.23 (1.03-1.46) 
Non-cardiovascular death 1.12 (0.99-1.26) 
 
Models adjusted for age, gender, renal function, haemoglobin and history of hypertension, stroke, peripheral vascular disease,  
diabetes mellitus, smoking, coronary artery disease and study phase.  
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Supplemental Table 4. Death and major cardiovascular events at 5 years stratified by diagnosis in those who survived index hospitalization  
 
 
 Type 1 MI  
(n=1,074) 
Type 2 MI 
(n=368) 
Myocardial injury 
(n=437) 
Type 2 MI versus  
Type 1 MI 
 
Adjusted RR  
(95% CI) 
Myocardial Injury 
versus Type 1 MI 
 
Adjusted RR  
(95% CI) 
Death from any cause 333 (31.0%) 207 (56.1%) 293 (67.0%) 1.52 (1.21-1.92) 1.95 (1.60-2.39) 
MACE  298 (27.7%) 101 (27.4%) 135 (30.9%) 0.80 (0.65-0.98) 0.87 (0.73-1.02) 
   Non-fatal MI  198 (18.4%) 41 (11.1%) 34 (7.8%) 0.60 (0.45-0.81) 0.46 (0.34-0.64) 
   Cardiovascular death 172 (16.0%) 77 (20.9%) 118 (27.0%) 0.95 (0.76-1.18) 1.07 (0.90-1.27) 
Fatal MI 32 (3.0%) 9 (2.4%) 17 (3.9%) 0.65 (0.38-1.14) 0.90 (0.61-1.31) 
Heart failure hospitalization 92 (8.6%) 22 (6.0%) 39 (8.9%) 0.86 (0.58-1.26) 1.18 (0.91-1.52) 
Non-cardiovascular death 145 (13.5%) 121 (32.8%) 162 (37.1%) 1.55 (1.28-1.88) 1.61 (1.38-1.88) 
	Supplemental Table 5. – Cause-specific hazard ratios for major adverse cardiovascular 
events in patients with type 2 myocardial infarction or myocardial injury alone who survive 
from their initial presentation to 30 days; unadjusted and fully adjusted cox-regression 
models. 
 
 
 Major Adverse Cardiovascular Events (MACE)  
 Unadjusted HR (95% CI) 
Adjusted HR 
(95% CI) 
Age (per 10-year increase) 1.56 (1.39-1.75) 1.53 (1.34-1.75) 
Sex (male) 1.08 (0.84-1.38) 1.26 (0.97-1.64) 
Haemoglobin (per 10 g/L reduction) 1.10 (1.04-1.16) 1.04 (0.99-1.10) 
eGFR (per 10 ml/min reduction) 1.16 (1.10-1.21) 1.11 (1.05-1.17) 
Smoking 0.86 (0.60-1.23) 1.39 (0.94-2.05) 
Diabetes Mellitus 1.79 (1.36-2.35) 1.50 (1.12-2.01) 
Hypertension 1.61 (1.24-2.10) 1.02 (0.76-1.36) 
Stroke 1.54 (1.12-2.13) 1.12 (0.80-1.55) 
Peripheral Vascular Disease 2.43 (1.68-3.50) 1.82 (1.21-2.74) 
Validation phase 1.19 (0.92-1.53) 1.25 (0.96-1.63) 
Coronary Artery Disease  2.21 (1.73-2.83) 1.71 (1.31-2.24) 
  eGFR = estimated glomerular filtration rate. Patients without coronary artery disease as referent group.   
 
 
 
	
 
 
	 
 
Supplemental Figure 1. – CONSORT Diagram with identification of the study population. 
Consecutive patients with elevation in cardiac troponin concentration were identified (≥0.05 
µg/L). We excluded patients who underwent elective procedures, residents not local to our 
region or with missing or incomplete records. After adjudication, we excluded those with Type 
3-5 myocardial infarction.  
	
	
	
 
  
Consecutive patients with 
troponin elevation (≥0.05 µg/L)
(n=2,929)
Validation phase
(n=1,202)
Implementation phase
(n=920)
Adjudicated Diagnosis
Type 1 MI (n=620)
Type 2 MI (n=236)
Myocardial Injury (n=346)
Adjudicated Diagnosis
Type 1 MI (n=551)
Type 2 MI (n=193)
Myocardial Injury (n=176)
Exclusions (n=764)
Elective Procedures (n=121)
Resident out with region (n=297)
Missing/incomplete hospital records (n=346)
Final Diagnosis 
(n=2,165)
Type 1 MI (n=1,171)
Type 2 MI (n=429)
Myocardial Injury (n=522)
Type 3 MI (n=12)
Type 4 MI (n=21)
Type 5 MI (n=10)
Study Population 
(n=2,122)
Exclusions (n=43)
Type 3-5 MI (n=43)
	Supplemental Appendix 1. Analysis code 
 
All analysis was performed using R (version 3.2.2) using the survival and cmprsk packages. 
For transparency, the analysis code is available open source via GitHub.3  
 
Available at https://github.com/a-r-chapman/type_2_outcomes 
	
  
Upper reference limit = 0.05 µg/L 
 
 
	
Supplemental Appendix 2. Additional information on diagnostic adjudication  
 
Criteria for adjudication of patients with myocardial necrosis 
 
 
Type 1 myocardial infarction 
 
Myocardial necrosis (any cardiac troponin I [cTnI] 
concentration above the upper reference limit) with rise 
and or fall in cTnI concentration where serial testing 
was available AND symptoms OR signs of myocardial 
ischaemia  
 
 
Type 2 myocardial infarction 
 
Myocardial necrosis (any cTnI concentration above the 
upper reference limit) with rise and or fall in cTnI 
concentration where serial testing was available AND 
symptoms OR signs of myocardial ischaemia AND 
evidence of increased oxygen demand (e.g. 
tachyarrhythmia, hypertrophy) or reduced supply (e.g. 
hypotension, hypoxia or anaemia) in context of 
alternative clinical diagnosis 
 
 
Myocardial injury 
 
Myocardial necrosis (any cTnI concentration above the 
upper reference limit) without symptoms OR signs of 
myocardial ischaemia in context of alternative clinical 
diagnosis  
 
 
The process of adjudication was conducted by two cardiologists independently. Both had access to the 
electronic patient record. The adjudicated diagnosis was reached by evaluating the attending clinicians 
documentation of the presenting complaint, past medical history, cardiovascular risk factors and clinical 
examination findings including routine observations (pulse, blood pressure, pulse oximetry, temperature 
and conscious level). All investigation results undertaken by the attending clinician were available for 
review, including biochemistry and haematology results, the 12 lead electrocardiogram, echocardiogram, 
chest X-ray and invasive coronary angiography findings when performed. Both adjudicating cardiologists 
had access to the final discharge letter documenting the attending clinicians’ final diagnosis. We did not 
apply specific criteria to define supply or demand imbalance,1 but adjudicated myocardial supply or demand 
imbalance on an individual patient basis, in line with most studies in this area.2 
	Supplemental Appendix 3. Additional information on classification of cardiovascular 
death 
ICD Code Definition 
Ischaemic heart diseases 
I20 Angina pectoris 
I21 Acute myocardial infarction 
I22 Subsequent myocardial infarction 
I23 Certain current complications from acute myocardial infarction 
I24 Other acute ischaemic heart diseases 
I25 Chronic ischaemic heart disease 
Other forms of heart disease 
I34 Non-rheumatic mitral valve disorders 
I35 Non-rheumatic aortic valve disorders 
I36 Non-rheumatic tricuspid valve disorders 
I37 Pulmonary valve disorders 
I42 Cardiomyopathy 
I43 Cardiomyopathy in diseases classified elsewhere 
I46 Cardiac arrest 
I48 Atrial fibrillation and flutter 
I49 Other cardiac arrhythmias 
I50 Heart failure 
I51 Complications and ill-defined descriptions of heart disease 
Cerebrovascular diseases 
I60 Subarachnoid haemorrhage 
I61 Intracerebral haemorrhage 
I62 Other nontraumatic intracerebral haemorrhage 
I63 Cerebral infarction 
I64 Stroke, not specified as haemorrhage or infarction 
	I65 Occlusion and stenosis of precerebral arteries, not resulting in infarction 
I66 Occlusion and stenosis of cerebral arteries, not resulting in infarction 
I67 Other cerebrovascular diseases 
I68 Cerebrovascular disorders in diseases classified elsewhere 
I69 Sequelae of cerebrovascular disease 
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